Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Literature DB >> 22237849

Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Leopold Sellner¹, Sascha Dietrich, Peter Dreger, Hanno Glimm, Thorsten Zenz.

Abstract

Chronic lymphocytic leukemia (CLL) shows a heterogeneous clinical course, which can be explained in part by prognostic factors. Most patients do not need treatment at the time of first diagnosis. The identification of prognostic factors is of major interest if strategies can be devised to treat patients according to their individual risk profile or biological subgroup. Currently, in spite of a wealth of prognostic factors, individualized treatment approaches in different genetic or risk groups are the exemption in CLL. This review summarizes the most important prognostic and predictive factors in CLL, with particular emphasis on factors affecting treatment decisions in clinical trials and routine practice.

Entities: Disease Species

Mesh：

Substances：
Biomarkers, Tumor

Year: 2012 PMID： 22237849 DOI： 10.1007/s11899-011-0110-1

Source DB: PubMed Journal: Curr Hematol Malig Rep ISSN： 1558-8211 Impact factor: 3.952

71 in total

1. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

Authors: Constantine S Tam; Susan O'Brien; William Wierda; Hagop Kantarjian; Sijin Wen; Kim-Anh Do; Deborah A Thomas; Jorge Cortes; Susan Lerner; Michael J Keating
Journal: Blood Date: 2008-04-14 Impact factor: 22.113

Review 2. How I treat CLL up front.

Authors: John G Gribben
Journal: Blood Date: 2009-10-22 Impact factor: 22.113

3. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia.

Authors: G Dighiero; K Maloum; B Desablens; B Cazin; M Navarro; R Leblay; M Leporrier; J Jaubert; G Lepeu; B Dreyfus; J L Binet; P Travade
Journal: N Engl J Med Date: 1998-05-21 Impact factor: 91.245

4. Localization of gene for human p53 tumour antigen to band 17p13.

Authors: M Isobe; B S Emanuel; D Givol; M Oren; C M Croce
Journal: Nature Date: 1986 Mar 6-12 Impact factor: 49.962

5. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).

Authors: Dolores Caballero; Jose A García-Marco; Rodrigo Martino; Victoria Mateos; José M Ribera; José Sarrá; Angel León; Guillermo Sanz; Javier de la Serna; Rafael Cabrera; Marcos González; Jorge Sierra; Jesús San Miguel
Journal: Clin Cancer Res Date: 2005-11-01 Impact factor: 12.531

6. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Authors: Xose S Puente; Magda Pinyol; Víctor Quesada; Laura Conde; Gonzalo R Ordóñez; Neus Villamor; Georgia Escaramis; Pedro Jares; Sílvia Beà; Marcos González-Díaz; Laia Bassaganyas; Tycho Baumann; Manel Juan; Mónica López-Guerra; Dolors Colomer; José M C Tubío; Cristina López; Alba Navarro; Cristian Tornador; Marta Aymerich; María Rozman; Jesús M Hernández; Diana A Puente; José M P Freije; Gloria Velasco; Ana Gutiérrez-Fernández; Dolors Costa; Anna Carrió; Sara Guijarro; Anna Enjuanes; Lluís Hernández; Jordi Yagüe; Pilar Nicolás; Carlos M Romeo-Casabona; Heinz Himmelbauer; Ester Castillo; Juliane C Dohm; Silvia de Sanjosé; Miguel A Piris; Enrique de Alava; Jesús San Miguel; Romina Royo; Josep L Gelpí; David Torrents; Modesto Orozco; David G Pisano; Alfonso Valencia; Roderic Guigó; Mónica Bayés; Simon Heath; Marta Gut; Peter Klatt; John Marshall; Keiran Raine; Lucy A Stebbings; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Ivo Gut; Armando López-Guillermo; Xavier Estivill; Emili Montserrat; Carlos López-Otín; Elías Campo
Journal: Nature Date: 2011-06-05 Impact factor: 49.962

7. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.

Authors: Marco Montillo; Alessandra Tedeschi; Sara Miqueleiz; Silvio Veronese; Roberto Cairoli; Liliana Intropido; Francesca Ricci; Anna Colosimo; Barbara Scarpati; Michela Montagna; Michele Nichelatti; Mario Regazzi; Enrica Morra
Journal: J Clin Oncol Date: 2006-04-17 Impact factor: 44.544

Review 8. From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors: Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal: Nat Rev Cancer Date: 2009-12-03 Impact factor: 60.716

9. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors: Gerard Lozanski; Nyla A Heerema; Ian W Flinn; Lisa Smith; Jennifer Harbison; Jennifer Webb; Mollie Moran; Margaret Lucas; Thomas Lin; Marcy L Hackbarth; John H Proffitt; David Lucas; Michael R Grever; John C Byrd
Journal: Blood Date: 2004-01-15 Impact factor: 22.113

10. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors: Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal: Cancer Cell Date: 2010-01-07 Impact factor: 31.743

4 in total

1. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.

Authors: Natali Pflug; Jasmin Bahlo; Tait D Shanafelt; Barbara F Eichhorst; Manuela A Bergmann; Thomas Elter; Kathrin Bauer; Gebhart Malchau; Kari G Rabe; Stephan Stilgenbauer; Hartmut Döhner; Ulrich Jäger; Michael J Eckart; Georg Hopfinger; Raymonde Busch; Anna-Maria Fink; Clemens-Martin Wendtner; Kirsten Fischer; Neil E Kay; Michael Hallek
Journal: Blood Date: 2014-05-05 Impact factor: 22.113